Drug · SMILES 확보 · Core 유사 84%
Exploration Score · catalog ranks
Rule-based Catalog Exploration Score for pharmacophore cores and drug/derivative nodes. Not an efficacy prediction.
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.
Derivative structure exploration tiers
Rule-based Catalog Exploration Score from SMILES similarity, approved/clinical tags, family network size, and SAR metadata. It does not predict efficacy, safety, or development success.
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.
How similarity is calculated · How clustering works · How exploration priority is scored
치료 영역 · 계열
HighHigh exploration priority18
Highest Exploration Score percentile in this pool (X-S bin)
| High exploration priority | 2D | Structure | Class | Exploration Score | Factors |
|---|---|---|---|---|---|
| High | Liraglutide GLP-1 / incretin agonist series · Drug | GLP-1 / incretin | 68 | Drug · SMILES 확보 · Core 유사 84% | |
| High | Semaglutide GLP-1 / incretin agonist series · Drug | GLP-1 / incretin | 68 | Drug · SMILES 확보 · Core 유사 84% | |
| High | Survodutide GLP-1 / incretin agonist series · Drug | GLP-1 / incretin | 65 | Drug · SMILES 확보 · Core 유사 72% | |
| High | Tirzepatide GLP-1 / incretin agonist series · Drug | GLP-1 / incretin | 65 | Drug · SMILES 확보 · Core 유사 72% | |
| High | Exenatide GLP-1 / incretin agonist series · Drug | GLP-1 / incretin | 64 | Drug · SMILES 확보 · Core 유사 67% | |
| High | Lisaftoclax BCL-2 BH3-mimetic inhibitor series · Drug | BCL-2 inhibitor | 63 | Drug · SMILES 확보 · Core 유사 77% | |
| High | Venetoclax BCL-2 BH3-mimetic inhibitor series · Drug | BCL-2 inhibitor | 63 | Drug · SMILES 확보 · Core 유사 77% | |
| High | Afatinib EGFR tyrosine kinase inhibitor series · Drug | EGFR TKI | 62 | Drug · SMILES 확보 · 중간 유사도 | |
| High | Dacomitinib EGFR tyrosine kinase inhibitor series · Drug | EGFR TKI | 62 | Drug · SMILES 확보 · 중간 유사도 | |
| High | Dapagliflozin SGLT2 inhibitor series · Drug | SGLT2 inhibitor | 62 | Drug · SMILES 확보 · Core 유사 73% | |
| High | Sotagliflozin SGLT2 inhibitor series · Drug | SGLT2 inhibitor | 62 | Drug · SMILES 확보 · Core 유사 73% | |
| High | Alprazolam Benzodiazepine GABA-A modulators · Drug | Anxiolytic · GABA | 61 | Drug · SMILES 확보 · 중간 유사도 | |
| High | Diazepam Benzodiazepine GABA-A modulators · Drug | Anxiolytic · GABA | 61 | Drug · SMILES 확보 · 중간 유사도 | |
| High | Empagliflozin SGLT2 inhibitor series · Drug | SGLT2 inhibitor | 61 | Drug · SMILES 확보 · Core 유사 66% | |
| High | Everolimus PI3K / AKT / mTOR inhibitor series · Drug | PI3K / AKT / mTOR | 61 | Drug · SMILES 확보 · Core 유사 87% | |
| High | Exatecan Exatecan / DXd (TOP1 inhibitor) payload family · Drug | TOP1 inhibitor | 61 | Drug · SMILES 확보 · Core 유사 76% | |
| High | Gefitinib EGFR tyrosine kinase inhibitor series · Drug | EGFR TKI | 61 | Drug · SMILES 확보 · 중간 유사도 | |
| High | Sirolimus PI3K / AKT / mTOR inhibitor series · Drug | PI3K / AKT / mTOR | 61 | Drug · SMILES 확보 · Core 유사 87% |
Drug · SMILES 확보 · Core 유사 84%
Drug · SMILES 확보 · Core 유사 72%
Drug · SMILES 확보 · Core 유사 72%
Drug · SMILES 확보 · Core 유사 67%
Drug · SMILES 확보 · Core 유사 77%
Drug · SMILES 확보 · Core 유사 77%
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · Core 유사 73%
Drug · SMILES 확보 · Core 유사 73%
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · Core 유사 66%
Drug · SMILES 확보 · Core 유사 87%
Drug · SMILES 확보 · Core 유사 76%
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · Core 유사 87%
MedMedium exploration priority31
Upper-mid Exploration Score percentile (X-A bin)
| High exploration priority | 2D | Structure | Class | Exploration Score | Factors |
|---|---|---|---|---|---|
| Med | Cabazitaxel Taxane diterpenoid series · Drug | Taxane / microtubule | 60 | Drug · SMILES 확보 · Core 유사 79% | |
| Med | Docetaxel Taxane diterpenoid series · Drug | Taxane / microtubule | 60 | Drug · SMILES 확보 · Core 유사 79% | |
| Med | Irinotecan SN-38 / irinotecan (TOP1) small-molecule series · Drug | TOP1 inhibitor | 60 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Paclitaxel Taxane diterpenoid series · Drug | Taxane / microtubule | 60 | Drug · SMILES 확보 · Core 유사 77% | |
| Med | Rubitecan SN-38 / irinotecan (TOP1) small-molecule series · Drug | TOP1 inhibitor | 60 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | SN-38 SN-38 / irinotecan (TOP1) small-molecule series · Drug | TOP1 inhibitor | 60 | Drug · SMILES 확보 · Core 유사 66% | |
| Med | Sumatriptan Migraine triptan series · Drug | Migraine · triptan | 60 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Topotecan SN-38 / irinotecan (TOP1) small-molecule series · Drug | TOP1 inhibitor | 60 | Drug · SMILES 확보 · Core 유사 66% | |
| Med | Zolmitriptan Migraine triptan series · Drug | Migraine · triptan | 60 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Atogepant CGRP gepant migraine series · Drug | Migraine · CGRP gepant | 59 | Drug · SMILES 확보 · Core 유사 81% | |
| Med | Imatinib BCR-ABL TKI chemical series · Drug | BCR-ABL TKI | 59 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Lazertinib EGFR tyrosine kinase inhibitor series · Drug | EGFR TKI | 59 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Midazolam Benzodiazepine GABA-A modulators · Drug | Anxiolytic · GABA | 59 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Rizatriptan Migraine triptan series · Drug | Migraine · triptan | 59 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Ubrogepant CGRP gepant migraine series · Drug | Migraine · CGRP gepant | 59 | Drug · SMILES 확보 · Core 유사 81% | |
| Med | Sonrotoclax BCL-2 BH3-mimetic inhibitor series · Drug | BCL-2 inhibitor | 58 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Baricitinib JAK inhibitor chemical series · Drug | JAK inhibitor | 57 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Clonazepam Benzodiazepine GABA-A modulators · Drug | Anxiolytic · GABA | 57 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Eletriptan Migraine triptan series · Drug | Migraine · triptan | 57 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Garsorasib KRAS G12C inhibitor chemical landscape · Drug | KRAS inhibitor | 57 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Lorazepam Benzodiazepine GABA-A modulators · Drug | Anxiolytic · GABA | 57 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Naratriptan Migraine triptan series · Drug | Migraine · triptan | 57 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Nilotinib BCR-ABL TKI chemical series · Drug | BCR-ABL TKI | 57 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Osimertinib EGFR tyrosine kinase inhibitor series · Drug | EGFR TKI | 57 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Ponatinib BCR-ABL TKI chemical series · Drug | BCR-ABL TKI | 57 | Drug · SMILES 확보 | |
| Med | Sotorasib KRAS G12C inhibitor chemical landscape · Drug | KRAS inhibitor | 57 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Carbidopa Parkinson dopaminergic / MAO-B series · Drug | Parkinson | 56 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Erlotinib EGFR tyrosine kinase inhibitor series · Drug | EGFR TKI | 56 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Levodopa Parkinson dopaminergic / MAO-B series · Drug | Parkinson | 56 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Palbociclib CDK4/6 inhibitor chemical series · Drug | CDK4/6 inhibitor | 56 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Ribociclib CDK4/6 inhibitor chemical series · Drug | CDK4/6 inhibitor | 56 | Drug · SMILES 확보 · 중간 유사도 |
Drug · SMILES 확보 · Core 유사 79%
Drug · SMILES 확보 · Core 유사 79%
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · Core 유사 77%
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · Core 유사 66%
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · Core 유사 66%
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · Core 유사 81%
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · Core 유사 81%
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
MedMedium exploration priority46
Mid-pool Exploration Score (X-B bin)
| High exploration priority | 2D | Structure | Class | Exploration Score | Factors |
|---|---|---|---|---|---|
| Med | SN-38 Exatecan / DXd (TOP1 inhibitor) payload family · Drug | TOP1 inhibitor | 56 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Canagliflozin SGLT2 inhibitor series · Drug | SGLT2 inhibitor | 55 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Divarasib KRAS G12C inhibitor chemical landscape · Drug | KRAS inhibitor | 55 | Drug · SMILES 확보 | |
| Med | Navitoclax BCL-2 BH3-mimetic inhibitor series · Drug | BCL-2 inhibitor | 55 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Ruxolitinib JAK inhibitor chemical series · Drug | JAK inhibitor | 55 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Amphetamine ADHD stimulant / non-stimulant series · Drug | ADHD | 54 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Ibrutinib BTK inhibitor chemical series · Drug | BTK inhibitor | 54 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Lisdexamfetamine ADHD stimulant / non-stimulant series · Drug | ADHD | 54 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Zanubrutinib BTK inhibitor chemical series · Drug | BTK inhibitor | 54 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Tofacitinib JAK inhibitor chemical series · Drug | JAK inhibitor | 53 | Drug · SMILES 확보 | |
| Med | Asciminib BCR-ABL TKI chemical series · Drug | BCR-ABL TKI | 52 | Drug · SMILES 확보 | |
| Med | Pravastatin Statin HMG-CoA reductase inhibitor series · Drug | Statin / HMG-CoA | 52 | Drug · SMILES 확보 | |
| Med | Atorvastatin Statin HMG-CoA reductase inhibitor series · Drug | Statin / HMG-CoA | 51 | Drug · SMILES 확보 | |
| Med | Olomorasib KRAS G12C inhibitor chemical landscape · Drug | KRAS inhibitor | 51 | Drug · SMILES 확보 | |
| Med | Quetiapine Atypical antipsychotic series · Drug | Antipsychotic | 51 | Drug · SMILES 확보 | |
| Med | RMC-6236 KRAS G12D / RAS(ON) inhibitor series · Drug | KRAS inhibitor | 51 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | RMC-9805 KRAS G12D / RAS(ON) inhibitor series · Drug | KRAS inhibitor | 51 | Drug · SMILES 확보 · 중간 유사도 | |
| Med | Safinamide Parkinson dopaminergic / MAO-B series · Drug | Parkinson | 51 | Drug · SMILES 확보 | |
| Med | Atomoxetine ADHD stimulant / non-stimulant series · Drug | ADHD | 50 | Drug · SMILES 확보 | |
| Med | Daridorexant Sleep / hypnotic series · Drug | Sleep · hypnotic | 50 | Drug · SMILES 확보 | |
| Med | Dasatinib BCR-ABL TKI chemical series · Drug | BCR-ABL TKI | 50 | Drug · SMILES 확보 | |
| Med | Larotrectinib RET / MET / NTRK oncogene TKI series · Drug | RET / MET / NTRK TKI | 50 | Drug · SMILES 확보 | |
| Med | Methylphenidate ADHD stimulant / non-stimulant series · Drug | ADHD | 50 | Drug · SMILES 확보 | |
| Med | Repotrectinib RET / MET / NTRK oncogene TKI series · Drug | RET / MET / NTRK TKI | 50 | Drug · SMILES 확보 | |
| Med | Simvastatin Statin HMG-CoA reductase inhibitor series · Drug | Statin / HMG-CoA | 50 | Drug · SMILES 확보 | |
| Med | Suvorexant Sleep / hypnotic series · Drug | Sleep · hypnotic | 50 | Drug · SMILES 확보 | |
| Med | Encorafenib BRAF / MEK inhibitor chemical series · Drug | BRAF / MEK | 49 | Drug · SMILES 확보 | |
| Med | Olanzapine Atypical antipsychotic series · Drug | Antipsychotic | 49 | Drug · SMILES 확보 | |
| Med | Rasagiline Parkinson dopaminergic / MAO-B series · Drug | Parkinson | 49 | Drug · SMILES 확보 | |
| Med | Ropinirole Parkinson dopaminergic / MAO-B series · Drug | Parkinson | 49 | Drug · SMILES 확보 | |
| Med | Rosuvastatin Statin HMG-CoA reductase inhibitor series · Drug | Statin / HMG-CoA | 49 | Drug · SMILES 확보 | |
| Med | Rotigotine Parkinson dopaminergic / MAO-B series · Drug | Parkinson | 49 | Drug · SMILES 확보 | |
| Med | Selegiline Parkinson dopaminergic / MAO-B series · Drug | Parkinson | 49 | Drug · SMILES 확보 | |
| Med | Upadacitinib JAK inhibitor chemical series · Drug | JAK inhibitor | 49 | Drug · SMILES 확보 | |
| Med | Abemaciclib CDK4/6 inhibitor chemical series · Drug | CDK4/6 inhibitor | 48 | Drug · SMILES 확보 | |
| Med | Adagrasib KRAS G12C inhibitor chemical landscape · Drug | KRAS inhibitor | 48 | Drug · SMILES 확보 | |
| Med | Cobimetinib BRAF / MEK inhibitor chemical series · Drug | BRAF / MEK | 48 | Drug · SMILES 확보 | |
| Med | Eszopiclone Sleep / hypnotic series · Drug | Sleep · hypnotic | 48 | Drug · SMILES 확보 | |
| Med | Fluoxetine SSRI / SNRI antidepressant series · Drug | Antidepressant · SSRI/SNRI | 48 | Drug · SMILES 확보 | |
| Med | Fluvoxamine SSRI / SNRI antidepressant series · Drug | Antidepressant · SSRI/SNRI | 48 | Drug · SMILES 확보 | |
| Med | Lemborexant Sleep / hypnotic series · Drug | Sleep · hypnotic | 48 | Drug · SMILES 확보 | |
| Med | Trametinib BRAF / MEK inhibitor chemical series · Drug | BRAF / MEK | 48 | Drug · SMILES 확보 | |
| Med | Acalabrutinib BTK inhibitor chemical series · Drug | BTK inhibitor | 47 | Drug · SMILES 확보 | |
| Med | Aripiprazole Atypical antipsychotic series · Drug | Antipsychotic | 47 | Drug · SMILES 확보 | |
| Med | ARV-110 PROTAC / bifunctional degrader series · Drug | PROTAC / degrader | 47 | Drug · SMILES 확보 | |
| Med | ARV-471 PROTAC / bifunctional degrader series · Drug | PROTAC / degrader | 47 | Drug · SMILES 확보 |
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보 · 중간 유사도
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
LowLow exploration priority59
Lower Exploration Score — still listed for inspection (X-C bin)
| High exploration priority | 2D | Structure | Class | Exploration Score | Factors |
|---|---|---|---|---|---|
| Low | Dabrafenib BRAF / MEK inhibitor chemical series · Drug | BRAF / MEK | 47 | Drug · SMILES 확보 | |
| Low | Enlicitide PCSK9 inhibitor chemical & modality series · Drug | PCSK9 / LDL-C | 47 | Drug · SMILES 확보 | |
| Low | Gabapentin Neuropathic gabapentinoid / SNRI series · Drug | Neuropathic · gabapentinoid | 47 | Drug · SMILES 확보 | |
| Low | Pirtobrutinib BTK inhibitor chemical series · Drug | BTK inhibitor | 47 | Drug · SMILES 확보 | |
| Low | Pregabalin Neuropathic gabapentinoid / SNRI series · Drug | Neuropathic · gabapentinoid | 47 | Drug · SMILES 확보 | |
| Low | Vemurafenib BRAF / MEK inhibitor chemical series · Drug | BRAF / MEK | 47 | Drug · SMILES 확보 | |
| Low | Olaparib PARP inhibitor chemical series · Drug | PARP inhibitor | 46 | Drug · SMILES 확보 | |
| Low | Talazoparib PARP inhibitor chemical series · Drug | PARP inhibitor | 46 | Drug · SMILES 확보 | |
| Low | Capmatinib RET / MET / NTRK oncogene TKI series · Drug | RET / MET / NTRK TKI | 42 | Drug · SMILES 확보 | |
| Low | Entacapone Parkinson dopaminergic / MAO-B series · Drug | Parkinson | 42 | Drug · SMILES 확보 | |
| Low | Entrectinib RET / MET / NTRK oncogene TKI series · Drug | RET / MET / NTRK TKI | 42 | Drug · SMILES 확보 | |
| Low | Pralsetinib RET / MET / NTRK oncogene TKI series · Drug | RET / MET / NTRK TKI | 42 | Drug · SMILES 확보 | |
| Low | Pramipexole Parkinson dopaminergic / MAO-B series · Drug | Parkinson | 42 | Drug · SMILES 확보 | |
| Low | Selpercatinib RET / MET / NTRK oncogene TKI series · Drug | RET / MET / NTRK TKI | 42 | Drug · SMILES 확보 | |
| Low | Tepotinib RET / MET / NTRK oncogene TKI series · Drug | RET / MET / NTRK TKI | 42 | Drug · SMILES 확보 | |
| Low | Escitalopram SSRI / SNRI antidepressant series · Drug | Antidepressant · SSRI/SNRI | 41 | Drug · SMILES 확보 | |
| Low | Guanfacine ADHD stimulant / non-stimulant series · Drug | ADHD | 41 | Drug · SMILES 확보 | |
| Low | MK-0616 PCSK9 inhibitor chemical & modality series · Derivative | PCSK9 / LDL-C | 41 | Derivative · SMILES 확보 | |
| Low | Orforglipron GLP-1 / incretin agonist series · Drug | GLP-1 / incretin | 41 | Drug · SMILES 확보 | |
| Low | Paroxetine SSRI / SNRI antidepressant series · Drug | Antidepressant · SSRI/SNRI | 41 | Drug · SMILES 확보 | |
| Low | Sertraline SSRI / SNRI antidepressant series · Drug | Antidepressant · SSRI/SNRI | 41 | Drug · SMILES 확보 | |
| Low | Venlafaxine SSRI / SNRI antidepressant series · Drug | Antidepressant · SSRI/SNRI | 41 | Drug · SMILES 확보 | |
| Low | Viloxazine ADHD stimulant / non-stimulant series · Drug | ADHD | 41 | Drug · SMILES 확보 | |
| Low | Zaleplon Sleep / hypnotic series · Drug | Sleep · hypnotic | 41 | Drug · SMILES 확보 | |
| Low | Zolpidem Sleep / hypnotic series · Drug | Sleep · hypnotic | 41 | Drug · SMILES 확보 | |
| Low | Alectinib ALK / ROS1 TKI chemical series · Drug | ALK / ROS1 TKI | 40 | Drug · SMILES 확보 | |
| Low | Alpelisib PI3K / AKT / mTOR inhibitor series · Drug | PI3K / AKT / mTOR | 40 | Drug · SMILES 확보 | |
| Low | Brigatinib ALK / ROS1 TKI chemical series · Drug | ALK / ROS1 TKI | 40 | Drug · SMILES 확보 | |
| Low | Capivasertib PI3K / AKT / mTOR inhibitor series · Drug | PI3K / AKT / mTOR | 40 | Drug · SMILES 확보 | |
| Low | Carbamazepine Antiepileptic drug chemical series · Drug | Antiepileptic · AED | 40 | Drug · SMILES 확보 | |
| Low | Crizotinib ALK / ROS1 TKI chemical series · Drug | ALK / ROS1 TKI | 40 | Drug · SMILES 확보 | |
| Low | Donepezil Cognitive modulator series · Drug | Cognition · dementia | 40 | Drug · SMILES 확보 | |
| Low | Duloxetine Neuropathic gabapentinoid / SNRI series · Drug | Neuropathic · gabapentinoid | 40 | Drug · SMILES 확보 | |
| Low | Edaravone ALS neuroprotectant series · Drug | ALS | 40 | Drug · SMILES 확보 | |
| Low | Fedratinib JAK inhibitor chemical series · Drug | JAK inhibitor | 40 | Drug · SMILES 확보 | |
| Low | Fingolimod MS S1P modulator series · Drug | MS · S1P | 40 | Drug · SMILES 확보 | |
| Low | Galantamine Cognitive modulator series · Drug | Cognition · dementia | 40 | Drug · SMILES 확보 | |
| Low | Inavolisib PI3K / AKT / mTOR inhibitor series · Drug | PI3K / AKT / mTOR | 40 | Drug · SMILES 확보 | |
| Low | Lamotrigine Antiepileptic drug chemical series · Drug | Antiepileptic · AED | 40 | Drug · SMILES 확보 | |
| Low | Levetiracetam Antiepileptic drug chemical series · Drug | Antiepileptic · AED | 40 | Drug · SMILES 확보 | |
| Low | Lorlatinib ALK / ROS1 TKI chemical series · Drug | ALK / ROS1 TKI | 40 | Drug · SMILES 확보 | |
| Low | Memantine Cognitive modulator series · Drug | Cognition · dementia | 40 | Drug · SMILES 확보 | |
| Low | Milnacipran Neuropathic gabapentinoid / SNRI series · Drug | Neuropathic · gabapentinoid | 40 | Drug · SMILES 확보 | |
| Low | Niraparib PARP inhibitor chemical series · Drug | PARP inhibitor | 40 | Drug · SMILES 확보 | |
| Low | Ozanimod MS S1P modulator series · Drug | MS · S1P | 40 | Drug · SMILES 확보 | |
| Low | Ponesimod MS S1P modulator series · Drug | MS · S1P | 40 | Drug · SMILES 확보 | |
| Low | Riluzole ALS neuroprotectant series · Drug | ALS | 40 | Drug · SMILES 확보 | |
| Low | Risperidone Atypical antipsychotic series · Drug | Antipsychotic | 40 | Drug · SMILES 확보 | |
| Low | Rivastigmine Cognitive modulator series · Drug | Cognition · dementia | 40 | Drug · SMILES 확보 | |
| Low | Rucaparib PARP inhibitor chemical series · Drug | PARP inhibitor | 40 | Drug · SMILES 확보 | |
| Low | Siponimod MS S1P modulator series · Drug | MS · S1P | 40 | Drug · SMILES 확보 | |
| Low | Sodium phenylbutyrate ALS neuroprotectant series · Drug | ALS | 40 | Drug · SMILES 확보 | |
| Low | Tapentadol Neuropathic gabapentinoid / SNRI series · Drug | Neuropathic · gabapentinoid | 40 | Drug · SMILES 확보 | |
| Low | Taurursodiol ALS neuroprotectant series · Drug | ALS | 40 | Drug · SMILES 확보 | |
| Low | Topiramate Antiepileptic drug chemical series · Drug | Antiepileptic · AED | 40 | Drug · SMILES 확보 | |
| Low | Valproic acid Antiepileptic drug chemical series · Drug | Antiepileptic · AED | 40 | Drug · SMILES 확보 | |
| Low | Daraxonrasib Daraxonrasib · RAS(ON) · Drug | KRAS inhibitor | 39 | Drug · SMILES 확보 | |
| Low | MRTX1133 KRAS G12D / RAS(ON) inhibitor series · Drug | KRAS inhibitor | 39 | Drug · SMILES 확보 | |
| Low | Rimegepant CGRP gepant migraine series · Drug | Migraine · CGRP gepant | 39 | Drug · SMILES 확보 |
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Derivative · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Drug · SMILES 확보
Actual weights, formula and input limits
Exploration score method
StructureMoa ranks are a rule-based Exploration Score. An LLM does not predict activity or efficacy. Role, SMILES, and relation signals inside each family are summed and cut into High / Medium / Low exploration priority.
Core tab
- scaffold / payload / linker role weights
- family center-compound bonus
- SMILES source (db · known · pubchem · inherited)
- relation-edge count and derived-child count
Derivative tab
- drug / derivative / adc candidates
- similarity to family center via Morgan fingerprint, radius 2, 2048 bits, Tanimoto
- Approval, clinical and lead tag bonuses have been removed.
Explore tab
- sparse SAR, cross-scaffold pairs, expansion leaves
- weakly linked nodes and catalog-coverage gaps
- relation graph + stored Morgan fingerprints
- category filters
Exploration-priority bins
- High (X-S): top ~12%
- Medium (X-A/X-B): ~12–62%
- Low (X-C): remainder (pools under 5 compounds stay Medium)
Internal exploration metric based on catalog and structural signals. Not a prediction of efficacy, safety, potency, or development success.
평가 시각: 2026. 10. 28. 오후 7:04:03 · 캐시 5분 · 전체 패밀리